Issue Highlights

Pancreatic adenocarcinoma is a highly fatal cancer. Although population-level screening is not recommended, the Cancer of the Pancreas Screening Consortium recently suggested periodic abdominal imaging (with endoscopic ultrasound or magnetic resonance imaging) to screen for pancreatic cancer in high-risk individuals with certain genetic disorders.
Source: Clinical Gastroenterology and Hepatology - Category: Gastroenterology Authors: Tags: Issue highlights Source Type: research

Related Links:

Background: The incidence of pancreatic adenocarcinoma (PDAC) in patients with chronic pancreatitis (CP) is as high as 5%. It is a commonly encountered diagnostic challenge in patients with CP on long-term follow-up.Summary: This review consolidates the existing literature on assessment of PDAC in background of CP, its evaluation through the available investigations, surgical management, and prognostication. Recent change in symptomatology of an otherwise stable CP should raise a suspicion of malignancy. Endoscopic ultrasound (EUS) is more specific and sensitive in establishing the diagnosis of PDAC compared to cross-secti...
Source: Digestive Diseases - Category: Gastroenterology Source Type: research
ConclusionsFLT-PET improves interobserver concordance in GTV definition. Further studies will focus on verification of these findings, pathologic verification of the FLT-PET signal, and optimization of the FLT-PET signal threshold for autosegmentation.
Source: Practical Radiation Oncology - Category: Cancer & Oncology Source Type: research
Conclusion.R0 resection, the goal of neoadjuvant treatment, can be achieved in 70% of patients presenting with locally advanced pancreatic cancer. The median DFS was 31 months (95% CI: 11. 3–51.1). No relationship was found with tumor size, degree of vascular involvement, carcinoembryonic antigen test (CEA), CA 19‐9, degree of tumor regression on scan, fall in CA 19‐9, or SUV on PET scan and subsequent survival.
Source: The Oncologist - Category: Cancer & Oncology Authors: Tags: Chinese Edition, Clinical Trial Results, Endocrinology Source Type: research
CONCLUSION: R0 resection, the goal of neoadjuvant treatment, can be achieved in 70% of patients presenting with locally advanced pancreatic cancer. The median DFS was 31 months (95% CI: 11. 3-51.1). No relationship was found with tumor size, degree of vascular involvement, carcinoembryonic antigen test (CEA), CA 19-9, degree of tumor regression on scan, fall in CA 19-9, or SUV on PET scan and subsequent survival. PMID: 29212734 [PubMed - as supplied by publisher]
Source: The Oncologist - Category: Cancer & Oncology Authors: Tags: Oncologist Source Type: research
Abstract: Initial imaging of pancreatic ductal adenocarcinoma is of crucial importance in the decision-making process. The aim of this study was to compare preoperative imaging, pathological data, and outcomes in a series of patients who underwent resection for pancreatic head cancer. From January 2004 to December 2009, data were collected by the Association Française de Chirurgie on 1044 patients who received first-line R0 resection of pancreatic head cancer. On imaging (computed tomography scan 97%, echoendoscopic ultrasound 61.3%, magnetic resonance imaging 46.5%), arterial, venous, or lymph node invasion was s...
Source: Medicine - Category: Internal Medicine Tags: Research Article: Observational Study Source Type: research
Authors: Bai Z, Shi Y, Wang J, Qiu L, Teng G, Zhang F, Yang X Abstract PURPOSE: To investigate the feasibility of using multi-modality imaging to monitor the creation of rat models with orthotopic pancreatic head cancer with obstructive jaundice. RESULTS: 27 of 52 rats (51.92%) developed pancreatic head cancer. The tumor formation rate was significantly higher in the animal group receiving bioluminescent tumor, compared to the group receiving non-bioluminescent donor tumors [78.1% (25/32 rats) vs 10.0% (2/20 rats), P = 0.0001]. Both ultrasound imaging and MRI clearly characterized the orthotopic tumors. Laborat...
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
Conclusions: This study provides evidence that the prevalence and growth characteristics of pancreatic cysts differ between distinct high-risk groups: individuals with FPC have a higher prevalence of pancreatic cysts 10 mm or greater, whereas cysts in mutation carriers are more likely to progress. These observations may help to develop more optimally tailored surveillance strategies in specific high-risk populations.
Source: Pancreas - Category: Gastroenterology Tags: Original Articles Source Type: research
Germline BRCA2 mutations are the first known cause of inherited (familial) pancreatic ductal adenocarcinoma (PDAC). This tumor is the third most frequent cancer in carriers of germline BRCA2 mutations, as it occurs in around 10% of BRCA2 families. PDAC is known as one of the most highly lethal cancers, mainly because of its chemoresistance and frequently late diagnosis. Based on recent developments in molecular biology, a subgroup of BRCA2-associated PDAC has been created, allowing screening, early surgical treatment and personalized systemic treatment. BRCA2 germline mutation carriers who have ≥1 first-degree relative,...
Source: Endocrine-Related Cancer - Category: Endocrinology Authors: Tags: Thematic Review Source Type: research
Synchronous primary pancreatic adenocarcinoma, defined as the simultaneous presence of 2 or more newly identified and anatomically separate primary adenocarcinomas within the pancreas, is rarely reported. We compared endoscopic ultrasound (EUS) and computed tomography (CT) and magnetic resonance imaging (MRI) findings from patients with synchronous primary pancreatic adenocarcinoma and their effects on cancer staging and treatment. We performed a retrospective analysis of the EUS database at the Mayo Clinic, from September 2008 through May 2016, to collect EUS, CT, MRI, and clinical data from patients with synchronous prim...
Source: Clinical Gastroenterology and Hepatology - Category: Gastroenterology Authors: Source Type: research
Conclusion Surveillance of CDNK2A mutation carriers is relatively successful, detecting most PDACs at a resectable stage. The benefit of surveillance in families with FPC is less evident.
Source: Journal of Clinical Oncology - Category: Cancer & Oncology Authors: Tags: Prognostic Studies, Population and observational studies (SEER, WHI observational, etc.) Cancer Prevention and Control Source Type: research
More News: Adenocarcinoma | Cancer | Cancer & Oncology | Gastroenterology | Genetics | MRI Scan | Pancreas | Pancreatic Cancer | Ultrasound